ORIENT BIO Inc. (002630.KS)
KRW 1430.0
(-13.07%)
KRW 1430.0
(-13.07%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.43 Billion KRW | 1346.46% |
| 2022 | 168.45 Million KRW | -91.27% |
| 2021 | 1.93 Billion KRW | 76.28% |
| 2020 | 1.09 Billion KRW | -45.68% |
| 2019 | 2.01 Billion KRW | 4022.78% |
| 2018 | 48.9 Million KRW | -99.6% |
| 2017 | 12.23 Billion KRW | 17.37% |
| 2016 | 10.42 Billion KRW | 3.09% |
| 2015 | 10.11 Billion KRW | 22.36% |
| 2014 | 8.26 Billion KRW | -29.56% |
| 2013 | 11.72 Billion KRW | 13.78% |
| 2012 | 10.3 Billion KRW | -14.19% |
| 2011 | 12.01 Billion KRW | 1126.01% |
| 2010 | 980 Million KRW | -39.02% |
| 2009 | 1.6 Billion KRW | -74.85% |
| 2008 | 6.39 Billion KRW | 4.87% |
| 2007 | 6.09 Billion KRW | -12.39% |
| 2006 | 6.95 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.41 Billion KRW | 0.0% |
| 2023 Q4 | 2.43 Billion KRW | 672.21% |
| 2023 FY | 2.43 Billion KRW | 1346.46% |
| 2023 Q1 | 138.96 Million KRW | -17.51% |
| 2023 Q2 | 108.88 Million KRW | -21.65% |
| 2023 Q3 | 315.53 Million KRW | 189.8% |
| 2022 Q4 | 168.45 Million KRW | -24.1% |
| 2022 Q1 | 579.56 Million KRW | 0.0% |
| 2022 Q3 | 221.95 Million KRW | -44.34% |
| 2022 Q2 | 398.78 Million KRW | -31.19% |
| 2022 FY | 168.45 Million KRW | -91.27% |
| 2021 Q2 | 2.06 Billion KRW | 15.04% |
| 2021 FY | 1.93 Billion KRW | 76.28% |
| 2021 Q1 | 1.79 Billion KRW | 63.79% |
| 2021 Q3 | 1.53 Billion KRW | -25.78% |
| 2020 Q1 | 2.65 Billion KRW | 31.49% |
| 2020 Q4 | 1.09 Billion KRW | 0.92% |
| 2020 Q3 | 1.08 Billion KRW | -24.43% |
| 2020 Q2 | 1.43 Billion KRW | -45.83% |
| 2020 FY | 1.09 Billion KRW | -45.68% |
| 2019 Q3 | 1.55 Billion KRW | 0.0% |
| 2019 Q1 | 48.9 Million KRW | 0.0% |
| 2019 Q2 | 1.55 Billion KRW | 3089.28% |
| 2019 FY | 2.01 Billion KRW | 4022.78% |
| 2019 Q4 | 2.01 Billion KRW | 29.27% |
| 2018 Q3 | 2.03 Billion KRW | -79.76% |
| 2018 FY | 48.9 Million KRW | -99.6% |
| 2018 Q4 | 48.9 Million KRW | -97.59% |
| 2018 Q2 | 10.03 Billion KRW | -18.0% |
| 2018 Q1 | 12.23 Billion KRW | 0.01% |
| 2017 FY | 12.23 Billion KRW | 17.37% |
| 2017 Q1 | 12.38 Billion KRW | 18.8% |
| 2017 Q4 | 12.23 Billion KRW | -0.97% |
| 2017 Q2 | 12.36 Billion KRW | -0.12% |
| 2017 Q3 | 12.35 Billion KRW | -0.12% |
| 2016 Q2 | 25.58 Billion KRW | -1.78% |
| 2016 Q1 | 26.05 Billion KRW | 157.67% |
| 2016 Q4 | 10.42 Billion KRW | -54.24% |
| 2016 Q3 | 22.77 Billion KRW | -10.97% |
| 2016 FY | 10.42 Billion KRW | 3.09% |
| 2015 FY | 10.11 Billion KRW | 22.36% |
| 2015 Q1 | 11.41 Billion KRW | 38.12% |
| 2015 Q4 | 10.11 Billion KRW | -35.34% |
| 2015 Q2 | 8.91 Billion KRW | -21.91% |
| 2015 Q3 | 15.63 Billion KRW | 75.43% |
| 2014 FY | 8.26 Billion KRW | -29.56% |
| 2014 Q4 | 8.26 Billion KRW | 6.44% |
| 2014 Q1 | 10.78 Billion KRW | -8.07% |
| 2014 Q2 | 7.17 Billion KRW | -33.46% |
| 2014 Q3 | 7.76 Billion KRW | 8.19% |
| 2013 Q2 | 12.82 Billion KRW | 20.27% |
| 2013 FY | 11.72 Billion KRW | 13.78% |
| 2013 Q4 | 11.72 Billion KRW | -5.22% |
| 2013 Q3 | 12.37 Billion KRW | -3.51% |
| 2013 Q1 | 10.66 Billion KRW | 3.45% |
| 2012 FY | 10.3 Billion KRW | -14.19% |
| 2012 Q4 | 10.3 Billion KRW | 0.0% |
| 2011 FY | 12.01 Billion KRW | 1126.01% |
| 2011 Q3 | 7.36 Billion KRW | 18.71% |
| 2011 Q2 | 6.2 Billion KRW | 638.1% |
| 2011 Q1 | 840 Million KRW | 0.0% |
| 2010 Q2 | 1.26 Billion KRW | -10.0% |
| 2010 Q3 | 1.12 Billion KRW | -11.11% |
| 2010 FY | 980 Million KRW | -39.02% |
| 2010 Q1 | 1.4 Billion KRW | 0.0% |
| 2009 Q2 | 2.01 Billion KRW | -9.2% |
| 2009 FY | 1.6 Billion KRW | -74.85% |
| 2009 Q3 | 1.81 Billion KRW | -10.17% |
| 2009 Q1 | 2.22 Billion KRW | 0.0% |
| 2008 Q2 | 3.77 Billion KRW | -35.82% |
| 2008 FY | 6.39 Billion KRW | 4.87% |
| 2008 Q3 | 2.24 Billion KRW | -40.63% |
| 2008 Q1 | 5.87 Billion KRW | 0.0% |
| 2007 Q2 | 6.56 Billion KRW | -11.17% |
| 2007 Q1 | 7.39 Billion KRW | 0.0% |
| 2007 Q3 | 6.4 Billion KRW | -2.38% |
| 2007 FY | 6.09 Billion KRW | -12.39% |
| 2006 FY | 6.95 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Green Cross Holdings Corporation | 216.35 Billion KRW | 98.874% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | 97.13% |
| Pharmicell Co., Ltd. | 390.21 Million KRW | -524.41% |
| Green Cross Corporation | 84.89 Billion KRW | 97.13% |
| GeneOne Life Science, Inc. | 6.27 Billion KRW | 61.157% |
| Celltrion, Inc. | 99.13 Billion KRW | 97.542% |
| Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 99.354% |
| SK bioscience Co.,Ltd. | 12.43 Billion KRW | 80.407% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | 97.421% |
| Prestige BioPharma Limited | 40.87 Billion KRW | 94.038% |